Publication:
Tricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine development

dc.contributor.authorTakeshi Miyataen_US
dc.contributor.authorTetsuya Harakunien_US
dc.contributor.authorTakafumi Tsuboien_US
dc.contributor.authorJetsumon Sattabongkoten_US
dc.contributor.authorAyumu Ikeharaen_US
dc.contributor.authorMayumi Tachibanaen_US
dc.contributor.authorMotomi Toriien_US
dc.contributor.authorGoro Matsuzakien_US
dc.contributor.authorTakeshi Arakawaen_US
dc.contributor.otherCOMBen_US
dc.contributor.otherEhime Universityen_US
dc.contributor.otherArmed Forces Research Institute of Medical Sciences, Thailanden_US
dc.contributor.otherUniversity of the Ryukyusen_US
dc.contributor.otherMahidol Universityen_US
dc.date.accessioned2018-05-03T08:14:54Z
dc.date.available2018-05-03T08:14:54Z
dc.date.issued2011-10-01en_US
dc.description.abstractThe creation of subunit vaccines to prevent malaria infection has been hampered by the intrinsically weak immunogenicity of the recombinant antigens. We have developed a novel strategy to increase immune responses by creating genetic fusion proteins to target specific antigen-presenting cells (APCs). The fusion complex was composed of three physically linked molecular entities: (i) a vaccine antigen, (ii) a multimeric α-helical coiled-coil core, and (iii) an APC-targeting ligand linked to the core via a flexible linker. The vaccine efficacy of the tricomponent complex was evaluated using an ookinete surface protein of Plasmodium vivax, Pvs25, and merozoite surface protein-1 of Plasmodium yoelii. Immunization of mice with the tricomponent complex induced a robust antibody response and conferred substantial levels of P. vivax transmission blockade as evaluated by a membrane feed assay, as well as protection from lethal P. yoelii infection. The observed effect was strongly dependent on the presence of all three components physically integrated as a fusion complex. This system, designated the tricomponent immunopotentiating system (TIPS), onto which any recombinant protein antigens or nonproteinaceous substances could be loaded, may be a promising strategy for devising subunit vaccines or adjuvants against various infectious diseases, including malaria. © 2011, American Society for Microbiology.en_US
dc.identifier.citationInfection and Immunity. Vol.79, No.10 (2011), 4260-4275en_US
dc.identifier.doi10.1128/IAI.05214-11en_US
dc.identifier.issn10985522en_US
dc.identifier.issn00199567en_US
dc.identifier.other2-s2.0-80855136511en_US
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/20.500.14594/11988
dc.rightsMahidol Universityen_US
dc.rights.holderSCOPUSen_US
dc.source.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80855136511&origin=inwarden_US
dc.subjectImmunology and Microbiologyen_US
dc.subjectMedicineen_US
dc.titleTricomponent immunopotentiating system as a novel molecular design strategy for malaria vaccine developmenten_US
dc.typeArticleen_US
dspace.entity.typePublication
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=80855136511&origin=inwarden_US

Files

Collections